Author + information
- Received July 7, 1987
- Revision received January 5, 1988
- Accepted January 20, 1988
- Published online June 1, 1988.
- Patricia A. Kelly, MD∗∗,
- David S. Cannom, MD, FACC†,
- Hasan Garan, MD, FACC∗,
- Gloria S. Mirabal, RN†,
- J.Warren Harthorne, MD, FACC∗,
- Richard J. Hurvitz, MD†,
- Gus J. Vlahakes, MD∗,
- Marshall L. Jacobs, MD∗,
- Joseph P. Ilvento, MD†,
- Mortimer J. Buckley, MD, FACC∗ and
- Jeremy N. Ruskin, MD, FACC∗
- ↵∗Address for reprints: Patricia Kelly, MD, Cardiac Unit, Massachusetts General Hospital, Fruit Street, Boston, Massachusetts 02114.
Ninety-four patients underwent surgery for automatic implanlable cardioverter-defibrillator implantation. Ninety patients were discharged from the hospital with the device and were followed up for a mean period of 17 ± 10 months. Forty-six patients experienced at least one discharge of the device under circumstances consistent with a malignant ventricular arrhythmia. One sudden death occurred. Complications included perioperative death (3 patients), post-operative ventricular tachycardia (12 patients) and atrial fibrillation (8 patients), perioperative myocardial infarction (1 patient) and device discharges for sinus tachycardia and supraventricular arrhythmias (17 patients).
Six and 12 month survival rates by life table analysis were 98.7 and 95.4%, respectively. Thus, the automatic implantable cardioverter-defibrillator is a highly effective and relatively low risk treatment modality for patients with refractory life-threatening ventricular arrhythmias.
☆ This study was supported in part by Grant #HL26215 from the National Institutes of Health, Bethesda, Maryland.
- Received July 7, 1987.
- Revision received January 5, 1988.
- Accepted January 20, 1988.